Who are Vasovist (BAY86-5283, MS-325)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Imeron, E-Z-Hd, Gadavist, Primovist, GADOFOSVESET, Optimark.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vasovist-bay86-5283-ms-325.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Vasovist (BAY86-5283, MS-325) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vasovist (BAY86-5283, MS-325) (Vasovist (BAY86-5283, MS-325)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Contrast agent. Area: Imaging.

phase 3 Contrast agent Imaging Small molecule Live · refreshed every 30 min

Target snapshot

Vasovist (BAY86-5283, MS-325) (Vasovist (BAY86-5283, MS-325)) — Bayer. Vasovist is a gadolinium-based contrast agent that works by enhancing the visibility of blood vessels in magnetic resonance imaging (MRI) scans.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Approval / PDUFA
Vasovist (BAY86-5283, MS-325) TARGET	Vasovist (BAY86-5283, MS-325)	Bayer	phase 3	Contrast agent
Imeron	IOMEPROL		marketed	Radiographic Contrast Agent [EPC]	2024-01-01
E-Z-Hd	BARIUM SULFATE		marketed	Radiographic Contrast Agent [EPC]	2016-01-01
Gadavist	GADOBUTROL	Bayer	marketed	Gadolinium-based Contrast Agent [EPC]	2011-01-01
Primovist	GADOXETIC ACID		marketed	Paramagnetic Contrast Agent	2008-01-01
GADOFOSVESET	GADOFOSVESET	Lantheus Medcl	marketed	Paramagnetic Contrast Agent	2008-01-01
Optimark	GADOVERSETAMIDE	Liebel-Flarsheim	marketed	Paramagnetic Contrast Agent	1999-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Contrast agent class)

Bayer · 2 drugs in this class
GE Healthcare · 1 drug in this class
University Hospital Muenster · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vasovist (BAY86-5283, MS-325) — Competitive Intelligence Brief. https://druglandscape.com/ci/vasovist-bay86-5283-ms-325. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab